DK175739B1 - Saponinadjuvans - Google Patents

Saponinadjuvans Download PDF

Info

Publication number
DK175739B1
DK175739B1 DK198906029A DK602989A DK175739B1 DK 175739 B1 DK175739 B1 DK 175739B1 DK 198906029 A DK198906029 A DK 198906029A DK 602989 A DK602989 A DK 602989A DK 175739 B1 DK175739 B1 DK 175739B1
Authority
DK
Denmark
Prior art keywords
saponin
methanol
adjuvant
extract
antigen
Prior art date
Application number
DK198906029A
Other languages
Danish (da)
English (en)
Other versions
DK602989A (da
DK602989D0 (da
Inventor
Charlotte A Kensil
Dante J Marciani
Gerald A Beltz
Chung-Ho Hung
Original Assignee
Antigenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21996520&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK175739(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Antigenics Inc filed Critical Antigenics Inc
Publication of DK602989A publication Critical patent/DK602989A/da
Publication of DK602989D0 publication Critical patent/DK602989D0/da
Application granted granted Critical
Publication of DK175739B1 publication Critical patent/DK175739B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J17/005—Glycosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/256—Polyterpene radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
DK198906029A 1987-05-29 1989-11-29 Saponinadjuvans DK175739B1 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5522987A 1987-05-29 1987-05-29
US5522987 1987-05-29
US8801842 1988-05-31
PCT/US1988/001842 WO1988009336A1 (fr) 1987-05-29 1988-05-31 Adjuvant a base de saponine

Publications (3)

Publication Number Publication Date
DK602989A DK602989A (da) 1989-11-29
DK602989D0 DK602989D0 (da) 1989-11-29
DK175739B1 true DK175739B1 (da) 2005-02-07

Family

ID=21996520

Family Applications (1)

Application Number Title Priority Date Filing Date
DK198906029A DK175739B1 (da) 1987-05-29 1989-11-29 Saponinadjuvans

Country Status (8)

Country Link
EP (1) EP0362279B2 (fr)
JP (1) JP2731563B2 (fr)
AT (1) ATE116993T1 (fr)
AU (1) AU616670B2 (fr)
CA (1) CA1331443C (fr)
DE (1) DE3852761T3 (fr)
DK (1) DK175739B1 (fr)
WO (1) WO1988009336A1 (fr)

Families Citing this family (159)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583112A (en) * 1987-05-29 1996-12-10 Cambridge Biotech Corporation Saponin-antigen conjugates and the use thereof
NZ230747A (en) * 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
NL9002314A (nl) * 1990-10-23 1992-05-18 Nederlanden Staat Immunogene complexen, in het bijzonder iscoms.
GB9202933D0 (en) * 1992-02-12 1992-03-25 Smithkline Beecham Biolog Vaccines
US5273965A (en) * 1992-07-02 1993-12-28 Cambridge Biotech Corporation Methods for enhancing drug delivery with modified saponins
US5650398A (en) * 1992-07-02 1997-07-22 Cambridge Biotech Corporation Drug delivery enhancement via modified saponins
NL9301690A (nl) * 1993-08-12 1995-04-18 Seed Capital Investments Verbindingen met adjuvans-activiteit.
AU1077795A (en) * 1993-09-30 1995-04-18 Seed Capital Investments (Sci) B.V. Compounds with adjuvant activity
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5597807A (en) * 1994-08-01 1997-01-28 University Of Saskatchewan Quinoa saponin compositions and methods of use
US5688772A (en) * 1994-08-01 1997-11-18 University Of Saskatchewan Quinoa saponin compositions and methods of use
AUPM873294A0 (en) * 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
EP0979100A1 (fr) * 1997-04-30 2000-02-16 Merieux OraVax SNC COMPOSITION VACCINALE ANTI-$i(HELICOBACTER) COMPRENANT UN ADJUVANT DE TYPE TH1
FR2762788B1 (fr) * 1997-04-30 2000-10-06 Pasteur Merieux Serums Vacc Composition vaccinale anti-helicobacter pour usage par voie systemique sous-diaphragmatique
FR2762787B1 (fr) * 1997-04-30 2000-10-06 Pasteur Merieux Serums Vacc Composition vaccinale anti-helicobacter comprenant un adjuvant de type th1
WO1998056415A1 (fr) * 1997-06-11 1998-12-17 Aquila Biopharmaceuticals, Inc. Saponines purifiees servant d'adjuvants oraux
US6241995B1 (en) 1997-08-08 2001-06-05 University Of Saskatchewan Polygala senega compositions and methods of use
US6686339B1 (en) 1998-08-20 2004-02-03 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
US6693087B1 (en) 1998-08-20 2004-02-17 Aventis Pasteur Limited Nucleic acid molecules encoding POMP91A protein of Chlamydia
EP1105490A1 (fr) 1998-08-20 2001-06-13 Aventis Pasteur Limited Molecules d'acide nucleique codant la proteine membrane d'inclusion c de chlamydia
PT1187629E (pt) 1999-04-19 2005-02-28 Glaxosmithkline Biolog Sa Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
DE60036698T2 (de) 1999-05-03 2008-07-24 Sanofi Pasteur Ltd., Toronto Chlamydia-antigene und entsprechende dna-fragmente und deren verwendungen
CA2721011A1 (fr) 1999-10-22 2001-05-03 Aventis Pasteur Limited Molecule gp100 modifiee et ses applications
EP1792995A3 (fr) 2000-05-08 2007-06-13 Sanofi Pasteur Limited Antigènes de chlamydia et fragments d'adn correspondants, et utilisations de ceux-ci
WO2001085932A2 (fr) 2000-05-10 2001-11-15 Aventis Pasteur Limited Polypeptides immunogeniques codes par des minigenes mage et leurs utilisations
PT2266603E (pt) 2000-10-18 2012-11-02 Glaxosmithkline Biolog Sa Vacinas tumorais
DE60239594D1 (de) 2001-02-23 2011-05-12 Glaxosmithkline Biolog Sa Influenza vakzinzusammensetzungen zur intradermaler verabreichung
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
US20100221284A1 (en) 2001-05-30 2010-09-02 Saech-Sisches Serumwerk Dresden Novel vaccine composition
TWI228420B (en) 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
PL376792A1 (pl) 2002-10-23 2006-01-09 Glaxosmithkline Biologicals S.A. Sposoby szczepienia przeciwko malarii
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
DE602005025342D1 (de) 2004-05-28 2011-01-27 Glaxosmithkline Biolog Sa Impfstoffzusammensetzungen mit virosomen und einem saponin-adjuvans
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
DK1838341T3 (da) 2005-01-20 2013-11-04 Isconova Ab Vaccinesammensætning omfattende et fibronectin bindende protein eller et fibronectinbindende peptid
GB0503337D0 (en) 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
GB0504436D0 (en) 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
ATE543832T1 (de) 2005-04-29 2012-02-15 Glaxosmithkline Biolog Sa Verfahren zur vorbeugung oder behandlung einer m.-tuberculosis-infektion
GB0513421D0 (en) 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
DK2495327T3 (da) 2006-03-03 2017-01-02 Promis Neurosciences Inc Fremgangsmåder og sammensætninger til at behandle og opdage sygdomme fremkaldt af fejlfoldet SOD1
WO2008030154A1 (fr) * 2006-09-08 2008-03-13 Hemocue Ab Agent d'hémolyse
TR201807756T4 (tr) 2006-09-26 2018-06-21 Infectious Disease Res Inst Sentetik adjuvan içeren aşı bileşimi.
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
MX2009009342A (es) 2007-03-02 2009-09-11 Glaxosmithkline Biolog Sa Metodo novedoso y composiciones.
EP2190470B1 (fr) 2007-08-13 2017-12-13 GlaxoSmithKline Biologicals SA Vaccins
AU2008299536B2 (en) 2007-09-11 2014-06-12 University Of Guelph Novel polysaccharide immunogens from clostridium difficile
CA2703947C (fr) 2007-10-26 2018-12-04 Governing Council Of The University Of Toronto Methodes therapeutiques et diagnostiques utilisant le tim-3
EP2062594A1 (fr) 2007-11-21 2009-05-27 Wyeth Farma, S.A. Vaccin de la fièvre catarrhale du mouton et compositions immunogènes, procédé d'utilisation et son procédé de production
EP4206231A1 (fr) 2007-12-24 2023-07-05 ID Biomedical Corporation of Quebec Antigènes du vrs recombinants
EP2293813A4 (fr) 2008-05-23 2012-07-11 Univ Michigan Vaccins à nanoémulsion
AU2009296458A1 (en) 2008-09-26 2010-04-01 Nanobio Corporation Nanoemulsion therapeutic compositions and methods of using the same
WO2010094663A1 (fr) 2009-02-17 2010-08-26 Glaxosmithkline Biologicals S.A. Vaccin à virus inactivé contre la dengue, contenant un adjuvant sans aluminium
EP2437753B1 (fr) 2009-06-05 2016-08-31 Infectious Disease Research Institute Adjuvants lipidiques synthétiques à base de glucopyranosyle et compositions de vaccin les contenant
CN102596243B (zh) 2009-06-16 2015-10-21 密执安大学评议会 纳米乳剂疫苗
WO2010149745A1 (fr) 2009-06-24 2010-12-29 Glaxosmithkline Biologicals S.A. Antigènes recombinants du vrs
MX2012000036A (es) 2009-06-24 2012-02-28 Glaxosmithkline Biolog Sa Vacuna.
HRP20220756T1 (hr) 2009-07-15 2022-09-02 Glaxosmithkline Biologicals S.A. Proteinski pripravci rsv f i postupci za izradu istih
US20110110980A1 (en) 2009-09-02 2011-05-12 Wyeth Llc Heterlogous prime-boost immunization regimen
KR101746880B1 (ko) 2009-09-10 2017-06-14 메리얼 인코포레이티드 사포닌-함유 면역보강제를 포함하는 신규 백신 제형
WO2011034950A1 (fr) 2009-09-16 2011-03-24 Vaxart, Inc. Stratégie d'immunisation pour empêcher une infection par le h1n1
US8658603B2 (en) 2010-06-16 2014-02-25 The Regents Of The University Of Michigan Compositions and methods for inducing an immune response
JP6133207B2 (ja) 2010-07-23 2017-05-24 イスコノバ アーベー インフルエンザワクチン
BR112013004582A2 (pt) 2010-09-27 2016-09-06 Crucell Holland Bv método para induzir uma resposta imune em um sujeito contra um antígeno de um parasita que causa a malária
AU2011315447A1 (en) 2010-10-15 2013-05-09 Glaxosmithkline Biologicals S.A. Cytomegalovirus gB antigen
EP3593813A1 (fr) 2010-12-14 2020-01-15 GlaxoSmithKline Biologicals S.A. Composition antigénique de mycobacterium
MD4177C1 (ro) * 2011-01-14 2013-02-28 Национальный Центр Общественного Здоровья Министерства Здравоохранения Республики Молдова Metodă de vaccinare contra hepatitei virale B a persoanelor imunocompromise
GB201106357D0 (en) 2011-04-14 2011-06-01 Pessi Antonello Composition and uses thereof
AU2012243039B2 (en) 2011-04-08 2017-07-13 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
SG11201400193SA (en) 2011-09-16 2014-05-29 Ucb Pharma Sa Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile
WO2013074501A1 (fr) 2011-11-14 2013-05-23 Crucell Holland B.V. Immunisation primovaccination-rappel hétérologue à l'aide de vaccins à base du virus de la rougeole
KR102024066B1 (ko) 2011-11-23 2019-09-24 비오벤 쓰리 리미티드 재조합 단백질 및 그들의 치료적 용도
CA3131037A1 (fr) 2011-11-30 2013-06-06 Emory University Inhibiteurs de jak antiviraux utiles dans le traitement ou la prevention d'infections retrovirales et autres infections virales
CN104363892A (zh) 2012-02-07 2015-02-18 传染性疾病研究院 包含tlr4激动剂的改进佐剂制剂及其使用方法
RS57420B1 (sr) 2012-05-16 2018-09-28 Immune Design Corp Vakcine za hsv-2
EP2666785A1 (fr) 2012-05-23 2013-11-27 Affiris AG Vaccins basés sur la protéine complément C5a
AU2013301312A1 (en) 2012-08-06 2015-03-19 Glaxosmithkline Biologicals S.A. Method for eliciting in infants an immune response against RSV and B. pertussis
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
EP2703483A1 (fr) 2012-08-29 2014-03-05 Affiris AG Vaccin à base de PCSK9
WO2014043189A1 (fr) 2012-09-14 2014-03-20 The Regents Of The University Of Colorado, A Body Corporate Virus de l'herpès déficients pour la réplication conditionnelle et leur utilisation dans des vaccins
UY34506A (es) * 2012-12-10 2014-06-30 Fernando Amaury Ferreira Chiesa Adyuvante de vacunación, preparación y vacunas que lo contienen
WO2014160463A1 (fr) 2013-03-13 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Protéines f de rsv pré-fusion et leur utilisation
AR095425A1 (es) 2013-03-15 2015-10-14 Glaxosmithkline Biologicals Sa Vacuna, uso y procedimiento para prevenir una infección por picornavirus
CN111978409B (zh) 2013-03-15 2024-01-26 因斯瑞拜奥有限公司 自组装合成蛋白
WO2014163558A1 (fr) 2013-04-01 2014-10-09 Moreinx Ab Nanoparticules, constituées de stérol et de saponine de quillaja saponaria molina, leur procédé de préparation et leur utilisation comme support pour des molécules amphipathiques ou hydrophobes dans le domaine médical, notamment pour le traitement du cancer, et composés alimentaires
CA2909221A1 (fr) 2013-04-18 2014-10-23 Immune Design Corp. Monotherapie par gla pour une utilisation dans le traitement du cancer
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
KR20160040290A (ko) 2013-08-05 2016-04-12 글락소스미스클라인 바이오로지칼즈 에스.에이. 조합 면역원성 조성물
JP6306700B2 (ja) 2013-11-01 2018-04-04 ユニバーシティ オブ オスロＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｏｓｌｏ アルブミン改変体及びその使用
US11452767B2 (en) 2013-11-15 2022-09-27 Oslo Universitetssykehus Hf CTL peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
WO2015092710A1 (fr) 2013-12-19 2015-06-25 Glaxosmithkline Biologicals, S.A. Administration simultanée controlatérale de vaccins
US11801223B2 (en) 2013-12-31 2023-10-31 Access To Advanced Health Institute Single vial vaccine formulations
CN106255508B (zh) 2014-02-20 2020-07-07 瓦克萨特公司 用于小肠递送的制剂
US11571472B2 (en) 2014-06-13 2023-02-07 Glaxosmithkline Biologicals Sa Immunogenic combinations
TW201623329A (zh) 2014-06-30 2016-07-01 亞佛瑞司股份有限公司 針對骨調素截斷變異體的疫苗及單株抗體暨其用途
EP3169699A4 (fr) 2014-07-18 2018-06-20 The University of Washington Compositions de vaccin anticancéreux et leurs méthodes d'utilisation
WO2016057921A1 (fr) 2014-10-10 2016-04-14 Baker Jr James R Compositions de nanoémulsions permettant de prévenir, de supprimer ou d'éliminer une maladie allergique et inflammatoire
AR102548A1 (es) 2014-11-07 2017-03-08 Takeda Vaccines Inc Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y uso
AR102547A1 (es) 2014-11-07 2017-03-08 Takeda Vaccines Inc Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
CA2977493C (fr) 2015-03-03 2023-05-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Plateforme d'affichage provenant de proteines d'enveloppe de spores bacteriennes
WO2016141320A2 (fr) 2015-03-05 2016-09-09 Northwestern University Virus non neuro-invasifs et leurs utilisations
WO2016200951A1 (fr) 2015-06-12 2016-12-15 Vaxart, Inc. Formulations pour l'administration dans l'intestin grêle d'antigènes du rsv et des norovirus
CN114796474A (zh) 2015-09-03 2022-07-29 诺瓦瓦克斯股份有限公司 具有改进的稳定性和免疫原性的疫苗组合物
EP3138579A1 (fr) 2015-09-05 2017-03-08 Biomay Ag Protéine de fusion pour son utilisation dans le traitement d'une infection par le virus de l'hépatite b
US10759837B2 (en) 2015-11-09 2020-09-01 The University Of British Columbia Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
KR20180088828A (ko) 2015-11-09 2018-08-07 더 유니버시티 오브 브리티쉬 콜롬비아 아밀로이드 베타에서의 n-말단 에피토프 및 이에 형태적으로-선택적인 항체
US10774120B2 (en) 2015-11-09 2020-09-15 The University Of British Columbia Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
WO2017158421A1 (fr) 2016-03-14 2017-09-21 University Of Oslo Immunoglobulines anti-virales synthétiques
CR20180445A (es) 2016-03-14 2019-02-08 Univ Oslo Inmunoglobulinas diseñadas por ingeniería genética con unión alterada al fcrn
US11173207B2 (en) 2016-05-19 2021-11-16 The Regents Of The University Of Michigan Adjuvant compositions
EP3471761A2 (fr) 2016-06-21 2019-04-24 University Of Oslo Fragments de vaccin de liaison à hla et leurs utilisations
CA3031135A1 (fr) 2016-07-18 2018-01-25 The University Of British Columbia Anticorps anti-beta-amyloide
CA3034124A1 (fr) 2016-08-23 2018-03-01 Glaxosmithkline Biologicals Sa Peptides de fusion avec des antigenes lies a des fragments courts de chaine invariante (cd74)
GB201614799D0 (en) 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
EP3295956A1 (fr) 2016-09-20 2018-03-21 Biomay Ag Construction de polypeptide comprenant des fragments d'allergenes
US11466292B2 (en) 2016-09-29 2022-10-11 Glaxosmithkline Biologicals Sa Compositions and methods of treatment
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
WO2018096396A1 (fr) 2016-11-22 2018-05-31 University Of Oslo Variants d'albumine et leurs utilisations
CA3045952A1 (fr) 2016-12-07 2018-06-14 Glaxosmithkline Biologicals Sa Nouveau procede
GB201620968D0 (en) 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
MX2019006349A (es) 2016-12-16 2019-08-22 Inst Res Biomedicine Proteinas recombinantes rsv f de prefusion nuevas y usos de las mismas.
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
US20200254083A1 (en) 2017-06-16 2020-08-13 Glaxosmithkline Biologicals Sa Method of treatment
BR112020001045A2 (pt) 2017-07-18 2020-09-08 In3Bio Ltd. proteínas sintéticas e usos terapêuticos das mesmas
CN111148509A (zh) 2017-07-24 2020-05-12 诺瓦瓦克斯股份有限公司 治疗呼吸系统疾病的方法和组合物
WO2019048928A1 (fr) 2017-09-07 2019-03-14 University Of Oslo Molécules de vaccin
WO2019048936A1 (fr) 2017-09-07 2019-03-14 University Of Oslo Molécules vaccinales
CN111315406A (zh) 2017-09-08 2020-06-19 传染病研究所 包括皂苷的脂质体调配物及其使用方法
WO2019052975A1 (fr) 2017-09-13 2019-03-21 Sanofi Pasteur Composition immunogène contre le cytomégalovirus humain
CN111511395B (zh) 2017-11-03 2024-10-15 武田疫苗股份有限公司 用于将寨卡病毒灭活和用于确定灭活完全性的方法
CA3083078A1 (fr) 2017-12-01 2019-06-06 Glaxosmithkline Biologicals Sa Purification de saponine
JP2021504429A (ja) 2017-12-01 2021-02-15 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニン抽出
GB201721068D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
SG11202009206QA (en) 2018-03-19 2020-10-29 Novavax Inc Multivalent influenza nanoparticle vaccines
EP3569612A1 (fr) 2018-05-18 2019-11-20 Biomay Ag Traitement et prévention d'allergies aux acariens
CN112638936A (zh) 2018-06-12 2021-04-09 葛兰素史密丝克莱恩生物有限公司 腺病毒多核苷酸和多肽
EP3581201A1 (fr) 2018-06-15 2019-12-18 GlaxoSmithKline Biologicals S.A. Escherichia coli o157:h7 polypeptides et leurs utilisations
MX2021001479A (es) 2018-08-07 2021-04-28 Glaxosmithkline Biologicals Sa Novedosos procesos y vacunas.
EP3849521A1 (fr) 2018-09-14 2021-07-21 Massachusetts Institute Of Technology Adjuvant vaccinal à base de nanoparticules, et méthodes d'utilisation associées
EP3897846A1 (fr) 2018-12-21 2021-10-27 GlaxoSmithKline Biologicals SA Méthodes d'induction d'une réponse immunitaire
CN113573730A (zh) 2019-03-05 2021-10-29 葛兰素史密斯克莱生物公司 乙型肝炎免疫方案和组合物
IT201900007060A1 (it) 2019-05-21 2020-11-21 St Superiore Di Sanita Cellule tumorali ingegnerizzate e loro usi
CN114340665A (zh) 2019-05-25 2022-04-12 传染病研究所 用于对佐剂疫苗乳剂进行喷雾干燥的组合物和方法
BR112021026132A2 (pt) 2019-06-25 2022-02-08 In3Bio Ltd Proteínas sintéticas quiméricas estabilizadas e usos terapêuticos das mesmas
IT201900012540A1 (it) 2019-07-22 2021-01-22 Humanitas Mirasole Spa Inibitori di CHI3L1 e loro usi
EP4004018A1 (fr) 2019-07-24 2022-06-01 GlaxoSmithKline Biologicals SA Protéines de cytomégalovirus humain modifiées
EP4058581A1 (fr) 2019-11-15 2022-09-21 Infectious Disease Research Institute Agoniste de rig-i et formulation d'adjuvant pour le traitement de tumeurs
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
EP4255919A2 (fr) 2020-12-02 2023-10-11 GlaxoSmithKline Biologicals S.A. Nouveaux antigènes
CN117320745A (zh) 2021-03-30 2023-12-29 维拉瓦克斯股份公司 Sars-cov-2亚单位疫苗
US20240156935A1 (en) 2021-03-31 2024-05-16 Vib Vzw Vaccine Compositions for Trypanosomatids
EP4405374A1 (fr) 2021-09-23 2024-07-31 Viravaxx AG Vaccin contre le virus de l'hépatite b induisant la production d'anticorps neutralisants spécifiques de pres
CN118510790A (zh) 2021-12-13 2024-08-16 美国政府(由卫生和人类服务部的部长所代表) 噬菌体λ-疫苗系统
WO2023114570A1 (fr) 2021-12-19 2023-06-22 Massachusetts Institute Of Technology Compositions et méthodes pour obtenir des réponses durables des centres germinatifs à une sensibilisation active
WO2023144665A1 (fr) 2022-01-28 2023-08-03 Glaxosmithkline Biologicals Sa Protéines de cytomégalovirus humain modifiées
WO2024133160A1 (fr) 2022-12-19 2024-06-27 Glaxosmithkline Biologicals Sa Compositions pour le traitement de l'hépatite b

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54132218A (en) * 1978-04-01 1979-10-15 Toyo Soda Mfg Co Ltd Separation of saponin constituents
FR2456116A1 (fr) * 1979-05-11 1980-12-05 Sarget Lab Nouvelle saponine triterpenique derivee de la caulophyllogenine et ses applications therapeutiques
DE3040246C2 (de) * 1979-10-29 1985-01-10 Osaka Chemical Laboratory Co., Ltd., Osaka Sojasaponine A↓1↓ und A↓2↓ und ihre Verwendung
JPS617286A (ja) * 1984-06-22 1986-01-13 Kishimoto Sangyo Kk 単離サポニン製造方法

Also Published As

Publication number Publication date
EP0362279A4 (fr) 1990-05-14
WO1988009336A1 (fr) 1988-12-01
EP0362279B2 (fr) 1999-11-03
DK602989A (da) 1989-11-29
AU1934088A (en) 1988-12-21
DK602989D0 (da) 1989-11-29
DE3852761T3 (de) 2000-06-21
JP2731563B2 (ja) 1998-03-25
CA1331443C (fr) 1994-08-16
JPH02504266A (ja) 1990-12-06
EP0362279B1 (fr) 1995-01-11
ATE116993T1 (de) 1995-01-15
DE3852761T2 (de) 1995-09-07
DE3852761D1 (de) 1995-02-23
EP0362279A1 (fr) 1990-04-11
AU616670B2 (en) 1991-11-07

Similar Documents

Publication Publication Date Title
DK175739B1 (da) Saponinadjuvans
US5057540A (en) Saponin adjuvant
JP3717511B2 (ja) サポニン−抗原複合物とその用途
Bomford et al. Adjuvanticity and ISCOM formation by structurally diverse saponins
US5977081A (en) Triterpene saponin analogs having adjuvant and immunostimulatory activity
JP2005534752A (ja) カンピロバクターグリカンおよびグリコペプチド
NZ230747A (en) Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
KR0184779B1 (ko) 퀼라야 사포나리아 몰리나로부터 분리정제된 사포닌 변이체, 이의 분리정제 방법 및 이를 함유하는 백신 제형
Horton et al. Analytical characterization of lipopolysaccharide antigens from seven strains of Pseudomonas aeruginosa
US7204983B2 (en) Lipoglycan compositions and methods of treating parasitic infections
WO1995009179A1 (fr) Composes presentant une activite d'adjuvant
EP0682527A1 (fr) Vaccin a base d'hydrate de carbone et reactif diagnostique pour la trichinose
EP1019087B1 (fr) Complexes immunostimulants a base de gangliosides et leurs utilisations
JP2002525339A (ja) ウイルス疾患のための炭水化物ワクチン
MXPA99010675A (en) Triterpene saponin analogs having adjuvant and immunostimulatory activity

Legal Events

Date Code Title Description
PUP Patent expired